Prostate Cancer Testing Kits Market - Forecast(2024 - 2030)

Prostate Cancer Testing Kits Market Overview

Prostate Cancer Testing Kits Market size is estimated to reach $1.9 billion by 2027, growing at a CAGR of 11.4% during the forecast period 2022-2027. The earliest step in testing for prostate cancer is a prostate-specific antigen (PSA) test. PSA is a protein prepared by the prostate, the tiny gland below the bladder. In certain cases, an elevated PSA level can be a sign of prostate cancer. However, not all elevated PSA levels are an indication of prostate cancer. PSA is also discovered in enlargement of the prostate (benign prostatic hyperplasia), infections and inflammation of the prostate (prostatitis). Since PSA is detected in the blood, a PSA test is normally taken with a finger prick. A PSA test will not offer sufficient information for a diagnosis; however, it may assist the physician in making a determination if cancer is probable and what to do next. While PSA tests once needed the patient to be present in a laboratory or at the office of the physician, a test can presently be administered from the home of the patient. PSA tests can also be utilized to evaluate the efficiency of treatments and supervise progress. The tests could be performed to supervise for recurrence of cancer or other conditions. As per Health line, the picks for the best at-home PSA tests include Lets Get Checked priced at $99, Allergy Test priced at &45, Pinnacle BioLabs priced at $49.99, imaware priced at $89 and Quest Direct priced at $69. Trans rectal ultrasound is a vital instrument in the detection and management of prostate cancer. Its role is to recognize and characterize focal lesions prior to capsular invasion and metastases and to lead biopsy of the prostate. Prostate Health Index is a test that foresees the hazard of having prostate cancer. Prostate Health Index is utilized instead of the PSA test for prostate cancer detection and prostate cancer screening. A digital rectal examination (or exam) is utilized to detect if one may have a prostate issue or prostate cancer. It includes the physician or nurse feeling the prostate by way of the wall of the back passage (rectum). One Prostate Cancer Testing Kits industry application is in prostate cancer diagnostics.

The heightening application of At Home PSA Prostate Cancer Test Kits for screening of prostate cancer and increasing utilization of trans rectal ultrasound for detection and management of prostate cancer is set to drive the Prostate Cancer Testing Kits Market. The soaring advantages of screening for prostate cancer like detecting prostate cancers that can be at great hazard of spreading, so that they can be treated prior to their spread thereby decreasing the possibility of a loss of life from prostate cancer in certain men and the inclination of certain men to be informed if they have prostate cancer are set to propel the growth of the Prostate Cancer Testing Kits Market during the forecast period 2022-2027. This represents the Prostate Cancer Testing Kits Industry Outlook.

Report Coverage

The report: “Prostate Cancer Testing Kits Market Report - Forecast (2022-2027)” by Industry ARC, covers an in-depth analysis of the following segments in the Prostate Cancer Testing Kits Market.

Key Takeaways

• Geographically, North America (Prostate Cancer Testing Kits Market) accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the great predominance of prostate cancer requiring the utilization of trans rectal ultrasound for detection and management of prostate cancer and the increasing government initiatives to expedite early diagnosis in the North American region.
• Prostate Cancer Testing Kits Market growth is being driven by the development of technologically progressive products including portable and fast prostate cancer screening kits, the increasing count of digital rectal examinations and the introduction of numerous investigations for superior prostate cancer diagnostics. However, owing to the predominantly inactive course of this ailment and the not particular character of the Prostate-Specific Antigen (PSA) test, the increased occurrence has broadly been connected with cancers that would not go on to bring about loss of life (clinically insignificant), resulting in an overdiagnosis challenge and a resultant overtreatment ramification. This is one of the major factors hampering the growth of Prostate Cancer Testing Kits Market. 
• Prostate Cancer Testing Kits Market Detailed Analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Prostate Cancer Testing Kits Market report. 

 Prostate Cancer Testing Kits Market: Market Share (%) By Region, 2021

 For more details on this report - Request for Sample

Prostate Cancer Testing Kits Market Segment Analysis – By Product Type:

The Prostate Cancer Testing Kits Market based on product type can be further segmented into Prostate-Specific Antigen Test Kit (AccuQuik Test Kits), PSA SPOT Test Kit, Galleri® Multi-Cancer Early Detection Test, Prostate Testing Kit PSA Professional Cancer Screening Tests 5 Tests, PSA Rapid Test Kits, At-Home PSA Test Kits and Others. The Prostate-Specific Antigen Test Kit (AccuQuik Test Kits) Segment held the largest prostate cancer testing kits market share in 2021. This growth is owing to the surging application of prostate-specific antigen test kit diagnostic test for detecting the level of prostate specific antigen which is utilized to diagnose prostate issues from specimens of serum/plasma. Prostate Cancer Testing Kits industry application may involve testing for prostate cancer or prostate cancer screening. The heightening application of AccuQuik Test Kits for the diagnosis of early prostate cancer is further propelling the growth of the Prostate-Specific Antigen Test Kit (AccuQuik Test Kits) segment.

Furthermore, the PSA Rapid Test Kits segment is estimated to grow with the fastest CAGR of 12.1% during the forecast period 2022-2027 owing to the heightening application of PSA rapid test kits, also termed one-step PSA tests, as an accelerated direct binding PSA immunoassay for the qualitative detection of Prostate Specific Antigen (PSA) in human serum specimen.

Prostate Cancer Testing Kits Market Segment Analysis – By End User:

The Prostate Cancer Testing Kits Market based on end user can be further segmented into Hospitals And Clinics, Ambulatory Surgical Centers, Diagnostic Centers, Cancer Research Centers and Others. The Diagnostic Centers Segment held the largest prostate cancer testing kits market share in 2021. This growth is owing to the surging application of different prostate cancer diagnostic techniques including the application of prostate cancer testing kits on patients as required. The diagnostic centers expedite strong, on-time, cost-effective and high-quality diagnostic care and services in the secure healthcare environment and are useful for outsourcing bulk diagnostics tests from consulting physicians/healthcare institutions for superior customer services which are further propelling the growth of this segment.

Furthermore, the Hospital And Clinics segment is estimated to grow with the fastest CAGR of 12.7% during the forecast period 2022-2027 owing to the extensive application of free and total Prostate-Specific Antigen (PSA) tests in hospitals and clinics and the increasing application of PCA3 test in a few private hospitals and clinics owing to the requirement of greater research regarding how capably it performs.

Prostate Cancer Testing Kits Market Segment Analysis – By Geography:

The Prostate Cancer Testing Kits Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America and Rest of the World. North America (Prostate Cancer Testing Kits Market) held the largest prostate cancer testing kits market share with 30% of the overall market in 2021. The growth of this region is owing to the agreeable government backing for prostate specific antigen (PSA) test in the U.S. in the North American region. The soaring existence of key players like AccuQuik Test KitTM in the U.S. and the increasing predominance of prostate cancer is further propelling the growth of the Prostate Cancer Testing Kits Market in the North American region.

Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR over the forecast period 2022-2027. This growth is owing to factors like the rising pervasiveness of chronic ailments attributed to the altered lifestyle based on intake of western diets and inactive lifestyle in the Asia-Pacific region. The increasing predominance of prostate cancer is further fuelling the progress of the Prostate Cancer Testing Kits Market in the Asia-Pacific region.

Prostate Cancer Testing Kits Market Drivers

Surging Accessibility of Prostate Cancer Testing Kits are Projected to Drive the Growth of Prostate Cancer Testing Kits Market:

Digital rectal examination and prostate-specific antigen tests are the typically utilized prostate cancer screening tests. Trans rectal ultrasound (TRUS) is a 5- to 15-minute outpatient procedure that utilizes sound waves to develop a video image of the prostate gland. The home prostate test kit is an effortless and reliable way to assess the PSA (Prostate Specific Antigen) level in the blood - which is useful to assist in diagnosing issues with the prostate. This home prostate test is a rapid test intended as an initial semi-quantitative test to discover PSA blood levels greater than 4ng/ml in whole blood. The test needs to be utilized as a screening test and as a support for diagnosing elevated levels of PSA. Any positive outcomes need to be followed up by a visit to the physician who may request further tests. The surging accessibility of Prostate Cancer Testing Kits is therefore fuelling the growth of the Prostate Cancer Testing Kits Market during the forecast period 2022-2027.

Soaring Innovations in Prostate Cancer Testing Kits are Expected to Boost the Growth of the Prostate Cancer Testing Kits Market:

Apart from the digital rectal examination were in, the health care provider inserts a gloved finger into the rectum and feels the prostate for hard, lumpy, or abnormal areas with the test consuming only a few minutes to finish, towering innovations in prostate cancer testing kits have been noted. A trans rectal ultrasound (TRUS) is an ultrasound technique that is utilized to view a man’s prostate and surrounding tissues. In January 2022, a novel medical development was constructed to offer fast and useful testing for men who may be potential prostate cancer patients. The screening kit involves a specially designed system that could relay any early warning signs of the condition. The principal purpose of the investigation was to advance the accessibility of this typically overlooked medical technology to communities with a high incidence of prostate cancer and individuals with restricted to no access to proper health care. The novel medical testing equipment for discovering hints of prostate cancer was presented in the form of minimal and economical architecture. The constituents of the screening kit include a small cube-shaped calibrating device that scales to 1.6 inches and a simple test strip. The device was produced to offer the essential details of prostate cancer by way of a rare marker termed as the prostate-specific antigen of PSA. The testing is not too complicated and is similar to other tests, needing just a single drop of blood from the subject. The prostate screening device does not consume too much time, permitting patients and experts to get a hold of the outcomes in just a few minutes. The samples will then be tested and the outcomes will be available in 10 to 15 minutes. Rapid testing offers a much quicker detection and can be used instantly for further insights and additional tests when required. The soaring innovations in Prostate Cancer Testing Kits are therefore driving the growth of the Prostate Cancer Testing Kits Industry during the forecast period 2022-2027.

Prostate Cancer Testing Kits Market Challenges

Challenges of Prostate Cancer and Limitations of Prostate-Specific Antigen (PSA) are Hampering the Growth of the Prostate Cancer Testing Kits Market:

Prostate cancer is the most typical non-skin cancer in men with nearly $12 billion spent annually on the treatment of prostate cancer. Nearly 500,000 biopsies are carried out every year on men, many of which are possibly inessential. It has been widely recognized, that the clinical challenges in prostate cancer are numerous and rely on the disease category at patient presentation. It is helpful to view prostate cancer in a range of distinct clinical categories as these categories will define not only the suitable treatments but also the present clinical challenges. Though prostate specific antigen (PSA) screening for prostate cancer has been a standard of care (SOC) for numerous years, its advantages have caused debate currently. The United States Preventive Services Task Force (USPSTF) altered its guidelines in 2018 advising men 55-69 years to make an informed selection and discuss with their physician whether PSA screening is right for them while suggesting against screening for men over 70 years of age. This alteration in guidance came about subsequent to a review of published data of 1.9 million men on the application of PSA testing to screen for cancer-based on the potential harms and advantages of PSA screening. The limitations of PSA include reduced sensitivity and specificity for prostate cancer and PSA levels being raised by benign prostatic hyperplasia (BPH) and prostatic inflammation or lower urinary tract infection. When PSA outcomes are in the “gray zone”, additional factors like age, family history, ethnicity and digital rectal examination (DRE) factor into the shared decision-making discussion about the prostate biopsy. PSA cannot differentiate high-grade from low-grade cancer and is not prostate cancer-specific These issues are thus hampering the growth of the Prostate Cancer Testing Kits Market.

Prostate Cancer Testing Kits Industry Outlook

Novel product launches, mergers and acquisitions, development of technologically progressive devices, partnerships and collaborations are key strategies adopted by players in the Prostate Cancer Testing Kits Market. The top 10 companies in the Prostate Cancer Testing Kits Market are:

1. AccuQuik Test KitTM
2. LetsGetChecked
3. Allergy Test
4. Pinnacle BioLabs
5. imaware
6. QuestDirect
7. SELFCheck Prostate (PSA) Health Home Test Kit
8. Galleri Test
9. Prostate Testing Kit PSA Professional Cancer Screening Tests 5 Tests
10. Rapidfor™ PSA Rapid Test Kit

Recent Developments

• In March 2022, LetsGetChecked, a leading healthcare solutions firm, declared that it will acquire Veritas Genetics Inc. and Veritas Intercontinental, pioneers in genomics that share a scalable platform allowing the rapid interpretation of genetic information from a single gene to the whole genome. These acquisitions indicate a critical advancement in LetsGetChecked’s mission to empower individuals to take control of their health and allow both consumers and healthcare partners to be more keyed up in healthcare management.
• In September 2020, Houston-based testing and screening provider imaware™ teamed with HALO Diagnostics (www.halodx.com) to advance early detection and link patients to the most recent advances in prostate cancer diagnostics and treatment solutions. imaware™ provides a self-collected testing solution for men to learn their PSA (Prostate Specific Antigen) level and evaluate their prostate cancer risk while also reducing doctor-patient interaction during the COVID-19 pandemic.
• In April 2020, Bio-Techne Corporation declared that Exosome Diagnostics, a Bio-Techne brand, is introducing an ExoDx™ Prostate Test At-Home Collection Kit for patients who are concerned regarding their prostate health index. Millions of men currently had appointments cancelled for significant procedures, like biopsy, to detect the presence of prostate cancer owing to Shelter in Place orders issued to decrease the spread of COVID-19. The at-home collection kit offers an instant and cost-efficient solution that allows a telemedicine/telehealth opportunity for physicians and their patients who share frustration, anxiety and fear over whether the patient harbors high-grade prostate cancer. This concludes the Prostate Cancer Testing Kits industry Outlook.

Relevant Reports